Susceptibilities of 45 clinical isolates of Proteus penneri - Wikidata - wikimedia - TriplyDB

Susceptibilities of 45 clinical isolates of Proteus penneri

Susceptibilities of 45 clinical isolates of Proteus penneri

http://www.wikidata.org/entity/Q24669683

about

Bacteremia and subcutaneous abscess caused by Proteus penneri in a neutropenic host Expanded clinical spectrum of infections caused by Proteus penneri Potential virulence factors of Proteus bacilli.Urease activity of Proteus penneri Analysis of antibiotic resistance determinants in Proteus penneri.

P2860

Q24647404-24742A1A-4879-4942-9925-2D79E6198B94 Q24647404-F07A60BD-02BD-4B02-A183-B2D1DF23DA60 Q24653687-958B33CE-2052-4DFB-B6D5-FD65711F0E79 Q36574211-D8FAE5C6-3FE1-4773-B4D6-3561304BFE32 Q37223445-E219CA8E-C86B-450D-8B7E-2533FB32DB88 Q54238975-DDE56CCE-29B3-4604-8862-9364D4E24E39

P2860

Susceptibilities of 45 clinical isolates of Proteus penneri

http://www.wikidata.org/entity/Q24669683

description

1984 nî lūn-bûn

@nan

1984 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

1984 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

1984年の論文

@ja

1984年論文

@yue

1984年論文

@zh-hant

1984年論文

@zh-hk

1984年論文

@zh-mo

1984年論文

@zh-tw

1984年论文

@wuu

name

Susceptibilities of 45 clinical isolates of Proteus penneri

@ast

Susceptibilities of 45 clinical isolates of Proteus penneri

@en

Susceptibilities of 45 clinical isolates of Proteus penneri

@nl

type

label

Susceptibilities of 45 clinical isolates of Proteus penneri

@ast

Susceptibilities of 45 clinical isolates of Proteus penneri

@en

Susceptibilities of 45 clinical isolates of Proteus penneri

@nl

prefLabel

Susceptibilities of 45 clinical isolates of Proteus penneri

@ast

Susceptibilities of 45 clinical isolates of Proteus penneri

@en

Susceptibilities of 45 clinical isolates of Proteus penneri

@nl

P1433

Q24669683-1AF211D2-8078-478B-9D42-67AB7D60E97B

P1476

Q24669683-33375A8C-C7FC-4271-A7D2-134F4DF4EA68

P2093

Q24669683-21C376F9-4D7A-4DEC-8DD2-71EBE14DD1B3

Q24669683-6070E7D9-689B-41EE-9981-4F679D8ABBAC

Q24669683-9350BCF2-DDE1-499E-85DB-5A11C2DDDC7D

P2860

Q24669683-05EEA829-77D4-4CCB-889C-3AF142D61120

Q24669683-065113F5-9E27-40A7-8EC4-19971F64F984

Q24669683-07756F9B-9D84-42A0-BFB2-4035903EA965

Q24669683-07F08C22-9436-43B5-A94C-BADB606FE2B7

Q24669683-0CC94CE2-34E8-4F3B-A3F4-F176B8D67C1A

Q24669683-1AD27FB5-4A27-4C3E-94B7-90217E915915

Q24669683-1CE1BDAB-C008-4299-83F8-A13E041E4909

Q24669683-1F793152-64AE-49FD-98A1-37973AB36586

Q24669683-2B6430EC-2B7A-45DA-BE15-4BB1185CFE08

Q24669683-2EAD7A36-6B27-403A-AB1E-020636FE4539

P304

Q24669683-FE1D3224-C9D7-48E1-AA0A-8DF5E7EC2C82

P31

Q24669683-ABA4E135-EE9A-473D-93CA-06E66CED64E1

P356

Q24669683-E151F3D0-0B49-4D8F-B649-C0CB96C8B39C

P407

Q24669683-1682297C-F52D-4076-908C-FAE8EB7379CD

P433

Q24669683-B84F8E6A-0553-480F-9615-B8B3F658D3C3

P478

Q24669683-5E12E6E9-63E8-4FC4-A2FB-EF961FC0C858

P577

Q24669683-A31CFAC0-9421-4E87-A32E-369D44495BF0

P5875

Q24669683-DD1419D4-027A-4454-BD97-724646BD300E

P698

Q24669683-02595751-2EB9-459F-ABA9-330EAB3B921F

P932

Q24669683-8962B613-E54D-43B3-8314-06DCFF0FD368

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Susceptibilities of 45 clinical isolates of Proteus penneri

@en

P2093

A Lee

http://www.w3.org/2001/XMLSchema#string

M Fuksa

http://www.w3.org/2001/XMLSchema#string

S Krajden

http://www.w3.org/2001/XMLSchema#string

P2860

Proteus penneri and urinary calculi formation

Identification of Proteus penneri sp. nov., formerly known as Proteus vulgaris indole negative or as Proteus vulgaris biogroup 1

Laboratory evaluation of a rapid, automatic susceptibility testing system: report of a collaborative study.

Comparative activities of 13 beta-lactam antibiotics

Cefotetan, a new cephamycin: comparison of in vitro antimicrobial activity with other cephems, beta-lactamase stability, and preliminary recommendations for disk diffusion testing.

Antimicrobial and beta-lactamase inhibitory activities of carpetimycins A and B, new carbapenem antibiotics.

Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin.

In vitro activity and beta-lactamase stability of U-63196E, a novel cephalosporin.

In vitro activity and beta-lactamase stability of cefodizime, an aminothiazolyl iminomethoxy cephalosporin.

Antibacterial activities of SM-1652 compared with those of other broad-spectrum cephalosporins.

P304

419-20

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.26.3.419

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

1984-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

16688577

http://www.w3.org/2001/XMLSchema#string

P698

6508270

http://www.w3.org/2001/XMLSchema#string

P932

176184

http://www.w3.org/2001/XMLSchema#string